IP Library Granted Patent US 7,939,468
Granted Patent B2
US 7,939,468 · App. 12/756,786 · Granted May 10, 2011

Methods of identifying compounds that target tRNA splicing endonuclease and uses of said compounds as anti-proliferative agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,939,468
App. No.
12/756,786
Granted
May 10, 2011
Kind
B2
Abstract

The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer.

Claims (14)

1. A method for identifying a compound that modulates the ability of animalia tRNA splicing endonuclease to produce mature tRNA, the method comprising:

(a) contacting a compound or a compound from a library of compounds with an animalia cell that contains the animalia tRNA splicing endonuclease and expresses a full-length protein encoded by the coding region of a reporter gene of a nucleic acid substrate, wherein the nucleic acid substrate comprises the coding region of a reporter gene and a tRNA intron in a mature domain of a precursor tRNA, and wherein the tRNA intron is contained within the nucleic acid substrate such that the transcribed mRNA from the coding region of the reporter gene is out of frame; and

(b) detecting the amount of full-length protein expressed, wherein an alteration in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from a library of compounds, or in the presence of a negative control indicates that the compound or the compound from the library of compounds modulates the ability of animalia tRNA splicing endonuclease to produce mature tRNA.

2. The method of claim 1 , wherein a decrease in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from the library of compounds, or the presence of a negative control indicates that the compound or the compound from the library of compounds reduces the ability of animalia tRNA splicing endonuclease to produce mature tRNA.

3. The method of claim 1 , wherein an increase in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from the library of compounds, or the presence of a negative control indicates that the compound or the compound from the library of compounds increases the ability of animalia tRNA splicing endonuclease to produce mature tRNA.

4. The method of claim 1 , 2 or 3 , wherein the coding region of the reporter gene encodes at least one or more coding regions of the reporter genes from the group consisting of firefly luciferase, renilla luciferase, click beetle luciferase, green fluorescent protein, yellow fluorescent protein, red fluorescent protein, cyan fluorescent protein, blue fluorescent protein, beta-galactosidase, beta-glucoronidase, beta-lactamase, chloramphenicol acetyltransferase, and alkaline phosphatase.

5. The method of claim 1 , 2 or 3 , wherein the animalia cell is a human cell.

6. The method of claim 4 , wherein the animalia cell is a human cell.

7. The method of claim 1 , 2 or 3 , wherein the animalia tRNA splicing endonuclease is a human tRNA splicing endonuclease.

8. The method of claim 4 , wherein the animalia tRNA splicing endonuclease is a human tRNA splicing endonuclease.

9. The method of claim 5 , wherein the animalia tRNA splicing endonuclease is a human tRNA splicing endonuclease.

10. The method of claim 1 , 2 or 3 , wherein the tRNA intron is in the coding region of the reporter gene.

11. The method of claim 4 , wherein the tRNA intron is in the coding region of the reporter gene.

12. The method of claim 5 , wherein the tRNA intron is in the coding region of the reporter gene.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 053209/0872 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF 6420591,6583309,6503713, 5843995,7029846,7056656, 6468969,6486305,6630294, 6989256,6627398,8247167, 9017935 PREVIOUSLY RECORDED ON REEL 042418 FRAME 0774. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 24, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043672/0096 →
SECURITY INTEREST Recorded May 8, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042418/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2010
From: TROTTA, CHRISTOPHER R.
To: PTC THERAPEUTICS, INC.
Reel/Frame 024404/0284 →